Description: PreveCeutical Medical Inc., a health sciences company, develops options for preventive and curative therapies utilizing organic and nature identical products. It has research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity; the Program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions. The company offers CELLB9 immune system booster, an oral solution containing polarized and potentiated essential minerals extracted from a peptide obtained from Caribbean blue scorpion venom. It also provides medicinal cannabis-based products. The company has a research and option agreement with University of Queensland; and the UniQuest Pty Limited to develop non-addictive analgesics for the treatment of pain. It also has a strategic research and development supply agreement with Aurora Cannabis to produce medical cannabis. PreveCeutical Medical Inc. is based in Vancouver, Canada.
Home Page: www.preveceutical.com
5428 Marine Drive
West Vancouver,
BC
V7W 2R2
Canada
Phone:
604 416 7777
Officers
| Name | Title |
|---|---|
| Mr. Stephen Van Deventer | Chairman, CEO & CFO |
| Dr. Makarand Jawadekar Ph.D. | Chief Science Officer, President & Director |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 3901.8343 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |